他拉唑帕利对比医生选择化疗在晚期乳腺癌伴胚系BRCA1/2突变患者中的生活质量:EMBRACA III期试验患者报告结局
EMBRACA III期试验中,他拉唑帕利对比医生选择化疗在HER2阴性晚期乳腺癌伴胚系BRCA1/2突变患者中显著改善PFS;本分析评估患者报告结局,显示他拉唑帕利组总体健康状态/生活质量较基线显著改善,而化疗组显著恶化,且多个功能与症状量表也观察到显著获益和至临床意义恶化时间的延迟。
要点
- 他拉唑帕利组总体健康状态/生活质量较基线显著改善,化疗组显著恶化。
- 总体健康状态/生活质量至临床意义恶化时间他拉唑帕利组显著延迟。
- 多个功能与症状量表也观察到显著改善和恶化时间延迟。
核心结论
- 接受他拉唑帕利治疗的患者在多个癌症相关和乳腺癌特异性症状、功能及总体健康状态/生活质量方面有显著总体改善和至临床意义恶化时间的显著延迟。
研究设计与样本
- EMBRACA III期试验,患者按2:1随机接受他拉唑帕利(1 mg每日口服)或医生选择化疗(卡培他滨、艾日布林、吉西他滨或长春瑞滨)。
- 患者报告结局采用EORTC QLQ-C30和QLQ-BR23问卷,在基线、每3周治疗周期开始及治疗结束时评估。
- 预设探索性分析包括纵向混合效应模型比较治疗组,以及总体健康状态/生活质量和所有功能与症状量表的至临床意义恶化时间分析。
主要发现
- 总体健康状态/生活质量估计总体变化:他拉唑帕利组较基线改善3.0(95%CI 1.2, 4.8),化疗组恶化-5.4(95%CI -8.8, -2.0),组间P < 0.0001。
- 总体健康状态/生活质量至临床意义恶化时间:他拉唑帕利组对比化疗组风险比0.38(95%CI 0.26, 0.55),中位时间分别为24.3个月和6.3个月,P < 0.0001。
- 多个功能和症状量表也观察到显著的总体变化和至临床意义恶化时间的显著延迟,均倾向于他拉唑帕利。
关键数值与推荐
- 他拉唑帕利1 mg每日口服;医生选择化疗包括卡培他滨、艾日布林、吉西他滨或长春瑞滨。
- 总体健康状态/生活质量至临床意义恶化时间中位:他拉唑帕利组24.3个月,化疗组6.3个月(HR 0.38,95%CI 0.26, 0.55;P < 0.0001)。
临床怎么用
- 对于HER2阴性晚期乳腺癌伴胚系BRCA1/2突变患者,他拉唑帕利在改善生存的同时可维持或改善生活质量,并延迟生活质量恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the EMBRACA phase III trial, talazoparib (1 mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician's choice of chemotherapy (PCT; capecitabine, eribulin, gemcitabine, or vinorelbine) in patients with HER2-negative advanced breast cancer carrying a germline BRCA1/2 mutation; we evaluated patient-reported outcomes (PROs). PATIENTS AND METHODS: Patients were randomized 2 : 1 to receive talazoparib or PCT. PROs were assessed at day 1 (baseline), the start of each treatment cycle (every 3 weeks), and at the end of treatment, using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-30) and its breast cancer module, QLQ-BR23. Prespecified exploratory analyses included a longitudinal mixed-effect model comparing treatment arms and a time to definitive clinically meaningful deterioration (TTD) analysis carried out in the global health status/quality of life (GHS/QoL), and all functional and symptom scales from the EORTC QLQ-C30 and -BR23 questionnaires. Between-arm TTD comparisons were made using a stratified log-rank test and a Cox proportional hazards model. RESULTS: Baseline scores were similar between arms. Statistically significant estimated overall improvement from baseline in GHS/QoL was seen for talazoparib compared with statistically significant deterioration for PCT {3.0 [95% confidence interval (CI) 1.2, 4.8] versus -5.4 [95% CI -8.8, -2.0]; between arms, P < 0.0001}. A statistically significant greater delay was observed in TTD in GHS/QoL, favoring talazoparib over PCT [hazard ratio, 0.38 (95% CI 0.26, 0.55; median, 24.3 versus 6.3 months, respectively; P < 0.0001)]. A statistically significant overall change and a statistically significant delay in TTD, all favoring talazoparib, were also observed in multiple functions and symptoms. CONCLUSION: Patients who received talazoparib had significant overall improvements and significant delay in TTD in multiple cancer-related and breast cancer-specific symptoms, functions, and GHS/QoL. CLINICALTRIALS.GOV: NCT01945775.
引用
- Ettl J, Quek RGW, Lee KH, et al. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018. PMID: 30124753. doi:10.1093/annonc/mdy257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。